The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Assessing the impact of response to HMA-based therapy on survival outcomes in HR-MDS
Benjamin Rolles, MD, Brigham and Women’s Hospital, Boston, MA, comments on the results of an analysis from the International Consortium for MDS (icMDS) VALIDATE Database, which assessed the impact of response to hypomethylating agent (HMA)-based therapy on survival outcomes in patients with high-risk myelodysplastic syndromes (HR-MDS) in the context of baseline clinical-molecular risk and transplant status. Dr Rolles notes that the findings suggest that treatment response is a significant predictor of overall survival (OS) in patients who did not undergo transplant but did not hold the same predictive value in those who proceeded to stem cell transplantation. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
I’m very happy to represent the Validate Consortium. It’s a big multi-institutional and international database from 30 different centers led by the Yale Cancer Center. The Validate Consortium focuses on high-risk MDS patients and even though MDS patients are not having a malignancy, the outcome is very bad, even with patients with a high IPSS-R risk score, and we are very much focusing on the interplay between baseline molecular risk in our abstract that we’re presenting here, treatment response, transplant, and time to transplant, and we try to link to an amazing publication published in 2024 by Tentori et al...
I’m very happy to represent the Validate Consortium. It’s a big multi-institutional and international database from 30 different centers led by the Yale Cancer Center. The Validate Consortium focuses on high-risk MDS patients and even though MDS patients are not having a malignancy, the outcome is very bad, even with patients with a high IPSS-R risk score, and we are very much focusing on the interplay between baseline molecular risk in our abstract that we’re presenting here, treatment response, transplant, and time to transplant, and we try to link to an amazing publication published in 2024 by Tentori et al., they showed that the time to transplant is very much important for high-risk MDS patients. And we are trying now to bring treatment response into consideration.
And what we found out is that treatment response in patients that did not undergo transplant is very important for overall survival. Patients that underwent transplant; treatment response was not so important or not important at all. So our analysis has some caveats. So regarding patient size, it was a retrospective study, and we bucketed patients into a composite complete response group and a non-composite complete response group, but we have indications that it might be more important for MDS patients with high risk to go into transplant, maybe better in a timely manner than waiting too much by waiting for treatment response.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
